The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Open accessAbstract
CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the pathophysiology and treatment of mood disorders. OBJECTIVE: To determine whether a rapid antidepressant effect can be achieved with an antagonist at the N-methyl-D-aspartate receptor in subjects with major depression. DESIGN: A randomized, placebo-controlled, double-blind crossover study from November 2004 to September 2005. SETTING: Mood Disorders Research Unit at the National Institute of Mental Health. Patients Eighteen subjects with DSM-IV major depression (treatment resistant). INTERVENTIONS: After a 2-week drug-free period, subjects were given an intravenous infusion of either ketamine hydrochloride (0.5 mg/kg) or placebo on 2 test days, a week apart. Subjects were rated at baseline and at 40, 80, 110, and 230 minutes and 1, 2, 3, and 7 days postinfusion. Main Outcome Measure Changes in scores on the primary efficacy measure, the 21-item Hamilton Depression Rating Scale. RESULTS: Subjects receiving ketamine showed significant improvement in depression compared with subjects receiving placebo within 110 minutes after injection, which remained significant throughout the following week. The effect size for the drug difference was very large (d = 1.46 [95% confidence interval, 0.91-2.01]) after 24 hours and moderate to large (d = 0.68 [95% confidence interval, 0.13-1.23]) after 1 week. Of the 17 subjects treated with ketamine, 71% met response and 29% met remission criteria the day following ketamine infusion. Thirty-five percent of subjects maintained response for at least 1 week. CONCLUSIONS: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Shortly thereafter, ketamine's robust antidepressant effects were confirmed in treatmentresistant depression (TRD) and bipolar disorder (BD) [5][6][7]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not only do they produce sustained therapeutic effects following a single administration, they also appear to have broad therapeutic potential”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Unlike traditional antidepressants, psychoplastogens produce both fast-acting and sustained beneficial behavioral effects after a single administration (Figure 1) (38–42).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The rapid-acting dissociative agent ketamine, which has shown its efficacy in treating depression, is known to increase BDNF levels (37, 38).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, other NMDAR antagonists do not show antidepressant effects (Zarate et al., 2006)”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Zarate et al., 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single dose of ketamine alleviates depressive symptoms within hours in patients who have failed to respond to two or more conventional antidepressants, and the effects are sustained for 7 to 10 days.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's anxiolytic effects have also been supported by placebo-controlled trials which demonstrated that the psychic anxiety item on the 21item HAM-D significantly improved after ketamine infusion (compared to saline); the psychic anxiety item was one of only four items to improve (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A power analysis based on ketamine's antidepressant effects was used to determine the sample size of 18 (Murrough et al, 2013a;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which induce similar immediate antidepressant response rates (71% at 28 hours for ketamine vs. 69% at 48 hours for psilocybin) 94”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
From Synaptic Dysfunction in Depression: Potential Therapeutic Targets (2012) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Ketamine, an antagonist of the glutamatergic N-methyl-D-aspartate (NMDA) receptor (an ionotropic glutamate receptor), was shown to exhibit rapid onset and robust, short-term antidepressant effect in patients with treatment-resistant depression (TRD) [1–3].”
From Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program (2020) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Racemic ketamine was obtained from the Yale-New Haven Hospital Pharmacy and administered intravenously by constant infusion over 40 minutes at a dose of 0.5mg/kg, which has consistently been shown to have robust and rapid antidepressant effects 7,8 , and is typically used clinically.”
From Imaging the effect of ketamine on synaptic density (SV2A) in the living brain (2022) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Several clinical studies suggest that ketamine may also have significant anxiolytic effects.”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“The results of the study are consistent with previous work suggesting that ketamine has anxiolytic effects in patients with major depression (Salvadore et al, 2009;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated the efficacy of ketamine for treatment-resistant depression (Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“The lack of efficacy in our trial is likely due the fact that in our study most patients had mild to moderate depression as opposed to the more severe treatment-resistant major depression studied in ketamine clinical trials (Murrough et al, 2013a;Murrough et al, 2013b;Zarate et al, 2006).”
From Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial (2018) · cites this paper as Zarate et al, 2006
The cited source says what the claim attributes to it.
In the citing paper
“Intravenous ketamine administered at subanesthetic doses was found to exhibit robust and rapid onset of efficacy in patients with treatment-resistant depression (9).”
The cited source says what the claim attributes to it.
In the citing paper
“whereas it typically does not produce the sustained antidepressant response of psilocybin (35% at week 1 for ketamine vs. 71% at 1 month for psilocybin). 73,94,95”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [94]
In the citing paper
“Subsequent randomized controlled trials (RCTs) replicated this finding, demonstrating a 60–70% response rate of ketamine in TRD populations.10–14”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
In the citing paper
“However, ketamine’s antidepressant properties are also transient, lasting an average of 1 week following a single infusion10–14 and 18–19 days following repeated infusions.15,16”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [11]
In the citing paper
“Diverse NMDA receptor antagonism has demonstrated rapid antidepressant efficacy in preclinical depression paradigms [24,29,70,71] and in some clinical trials [72,73].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
In the citing paper
“Comparable results have been replicated in several similarly designed RDBPCTs examining single administration of sub-anesthetic dose ketamine in patients with MDD and TRD [73,91,92,93].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [73]
In the citing paper
“Extensive experience with human patients has established that ketamine exerts rapid, robust antidepressant, antianhedonic, and antisuicidal actions within two hours of administration that are sustained for at least seven days in patients with major depression following a single infusion or intranasal administration [129-133].”
From Plasticity of synapses and reward circuit function in the genesis and treatment of depression (2023) · cites this paper as [130]
In the citing paper
“Ketamine’s therapeutic effects occur within hours, with the strongest effect sizes observed at one day post-administration (Zarate et al., 2006).”
From Clinical indicators of the suicide crisis and response to ketamine (2025) · cites this paper as Zarate et al., 2006
In the citing paper
“A single, intravenous or intranasal sub-anesthetic dose of ketamine, a non-competitive NMDA glutamate receptor channel blocker, produces a rapid onset of antidepressant response that can last several days in the majority of treatment resistant unipolar and bipolar depressed patients participating in a growing number of clinical trials148–150.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [150]
In the citing paper
“Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative anesthetic ketamine induces rapid and sustained antidepressant actions in treatment-resistant patients.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
In the citing paper
“A subsequent double-blind randomized clinical trial demonstrated the efficacy of ketamine in treatment-resistant major depressed patients, who failed at least two conventional antidepressant treatments 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
In the citing paper
“The antidepressant effects of ketamine manifested within 2 hours post-infusion and 35% of patients maintained response for at least 7 days 5.”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Nestler, E. J., Barrot, M., DiLeone, R. J., Eisch, A. J., Gold, S. J., & Monteggia, L. M. (2002) · Neuron · doi:10.1016/s0896-6273(02)00653-0 · Cited by 3,217
Frank, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810330075011 · Cited by 1,959
Assessment of Depression: The Depression Inventory
Beck, A. T., & Beamesderfer, A. (2015) · Modern problems of pharmacopsychiatry/Modern trends in pharmacopsychiatry · doi:10.1159/000395074 · Cited by 1,860
A Growing Edge of Measurement of Feelings [ Abridged ]
Aitken, R. C. B. (1969) · Proceedings of the Royal Society of Medicine · doi:10.1177/003591576906201005 · Cited by 1,540
Ostwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
Flagged first, then by citations
Research works printed but not linked: 4
- [7]7. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobi- ology of depression. Neuron. 2002;34:13-25.
- [27]27. First MB, Spitzer RL, Gibbon M, Williams AR. Structured Clinical Interview for DSM-IV TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York: New York State Psychiatric Institute, Biometrics Research; 2001.
- [33]33. Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med. 1969;62:989-993.
- [42]42. Zarate CAJ, Singh J, Quiroz J, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind placebo-controlled study of memantine in ma- jor depression. Am J Psychiatry. 2006;163:153-155.
Cited by
Sorted by citations
Items 501–600 of 1,095
Deyama, S., Bang, E., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.12.014 · Cited by 116
mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants
Chaki, S., Ago, Y., Pałucha-Poniewiera, A., Matrisciano, F., & Pilc, A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.022 · Cited by 116
Glutamate-Based Antidepressants: Preclinical Psychopharmacology
Pilc, A., Wierońska, J. M., & Skolnick, P. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.01.021 · Cited by 119
Dong, C., Zhang, J.-C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., & Hashimoto, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw089 · Cited by 120
Bühre, W., Disma, N. M., Hendrickx, J. F. A., Hert, S. G. D., Hollmann, M. W., Huhn, R., Jakobsson, J., Nägele, P., Peyton, P. J., & Vutskits, L. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2019.01.023 · Cited by 116
Zanos, P., Brown, K. A., Georgiou, P., Yuan, P., Zarate, C. A., Thompson, S. M., & Gould, T. D. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1316-22.2022 · Cited by 115
Self-citationCan, A., Zanos, P., Moaddel, R., Kang, H. J., Dossou, K. S. S., Wainer, I. W., Cheer, J. F., Frost, D. O., Huang, X.-P., & Gould, T. D. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.235838 · Cited by 115
Koike, H., Iijima, M., & Chaki, S. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.034 · Cited by 114
The treatment of depressive disorders in epilepsy: What all neurologists should know
Kanner, A. M. (2013) · Epilepsia · doi:10.1111/epi.12100 · Cited by 115
Han, Y. K., Chen, J., Zou, D., Zheng, P., Li, Q., Wang, H., Li, P., Zhou, X., Zhang, Y., Liu, Y., et al. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s117146 · Cited by 115
Shiroma, P. R., THURAS, P. D., Wels, J., Albott, C. S., Erbes, C. R., Tye, S. J., & Lim, K. O. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00897-0 · Cited by 124
Ren, Z., Pribiag, H., Jefferson, S. J., Shorey, M., Fuchs, T., Stellwagen, D., & Luscher, B. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.02.009 · Cited by 114
History of anaesthesia: The ketamine story – past, present and future
Mion, G. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000638 · Cited by 113
Ma, X., Dang, Y., Jia, M., Ma, R., Wang, F., Wu, J., Gao, C., & Hashimoto, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056053 · Cited by 118
Mood-stabilizing drugs: mechanisms of action
Schloesser, R. J., Martinowich, K., & Manji, H. K. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.009 · Cited by 121
Self-citationDomany, Y., Bleich‐Cohen, M., Tarrasch, R., Meidan, R., Litvak-Lazar, O., Stoppleman, N., Schreiber, S., Bloch, M., Hendler, T., & Sharon, H. (2018) · The British Journal of Psychiatry · doi:10.1192/bjp.2018.196 · Cited by 114
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
Self-citationSustained Effects of Rapidly Acting Antidepressants Require BDNF-Dependent MeCP2 Phosphorylation
Kim, J.-W., Autry, A. E., Na, E. S., Adachi, M., Björkholm, C., Kavalali, E. T., & Monteggia, L. M. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00868-8 · Cited by 113
Ekstrand, J., Fattah, C., Persson, M., Cheng, T., Nordanskog, P., Åkeson, J., Tingström, A., Lindström, M. B., Nordenskjöld, A., & Movahed Rad, P. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab088 · Cited by 113
Mental Health and Emergency Medicine: A Research Agenda
Larkin, G. L., Beautrais, A. L., Spirito, A., Kirrane, B. M., Lippmann, M. J., & Milzman, D. P. (2009) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2009.00545.x · Cited by 113
An open-label, flexible-dose study of memantine in major depressive disorder
Ferguson, J. M., & Shingleton, R. N. (2007) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180314ae7 · Cited by 113
O'Connor, R. M., Grenham, S., Dinan, T. G., & Cryan, J. F. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000448 · Cited by 114
PKA-CREB-BDNF signaling regulated long lasting antidepressant activities of Yueju but not ketamine
Xue, W., Wang, W., Gong, T., Zhang, H., Tao, W., Xue, L., Sun, Y., Wang, F., & Chen, G. (2016) · Scientific Reports · doi:10.1038/srep26331 · Cited by 112
Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs
Musazzi, L., Racagni, G., & Popoli, M. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.05.002 · Cited by 118
The Interface of Pain and Mood Disturbances in the Rheumatic Diseases
Goldenberg, D. L. (2009) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.005 · Cited by 115
Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders
de Oliveira, R. M. W., Guimarães, F. S., & Deakin, J. F. W. (2008) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2008000400012 · Cited by 113
Abdallah, C. G., Averill, C. L., Salas, R., Averill, L. A., Baldwin, P. R., Krystal, J. H., Mathew, S. J., & Mathalon, D. H. (2017) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.04.006 · Cited by 111
Réus, G. Z., Stringari, R. B., Kirsch, T. R., Fries, G. R., Kapczinski, F. P., Roesler, R., & Quevedo, J. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.11.013 · Cited by 112
How does ketamine elicit a rapid antidepressant response?
Kavalali, E. T., & Monteggia, L. M. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.11.005 · Cited by 113
Differential effects of antidepressant drugs on mTOR signalling in rat hippocampal neurons
Park, S. W., Lee, J. G., Seo, M. K., Lee, C. H., Cho, H. Y., Lee, B. J., Seol, W., & Kim, Y. H. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000534 · Cited by 113
Cusin, C., Ionescu, D. F., Pavone, K. J., Akeju, O., Cassano, P., Taylor, N. E., Eikermann, M., Durham, K. E., Swee, M. B., Chang, T. E., et al. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416631828 · Cited by 114
Ketamine as an Adjuvant for Treatment of Cancer Pain in Children and Adolescents
Finkel, J. C., Pestieau, S. R., & Quezado, Z. (2007) · Journal of Pain · doi:10.1016/j.jpain.2007.02.429 · Cited by 111
Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals
Mkrtchian, A., Evans, J. W., Kraus, C., Yuan, P., Kadriu, B., Nugent, A. C., Roiser, J. P., & Zarate, C. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-00878-1 · Cited by 110
Self-citationCarvalho, A. F., Cavalcante, J. L., Castelo, M. S., & Lima, M. C. O. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00846.x · Cited by 110
Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?
Cardamone, L., Salzberg, M., O'Brien, T. J., & Jones, N. C. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12052 · Cited by 111
Administration of ketamine for unipolar and bipolar depression
Kraus, C., Rabl, U., Vanicek, T., Carlberg, L., Popovic, A., Spies, M., Bartova, L., Gryglewski, G., Papageorgiou, K., Lanzenberger, R. R., et al. (2017) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2016.1254802 · Cited by 114
Zhou, H., Zhang, Q., Martinez, E., Dale, J., Hu, S., Zhang, E., Liu, K. G., Huang, D., Yang, G., Chen, Z. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06295-x · Cited by 113
Murrough, J. W., Collins, K. A., Fields, J., DeWilde, K. E., Phillips, M. L., Mathew, S. J., Wong, E., Tang, C. Y., Charney, D. S., & Iosifescu, D. V. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.10 · Cited by 109
Self-citationPilot dose–response trial of i.v. ketamine in treatment-resistant depression
Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., Harper, S., & Loo, C. K. A. (2014) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.922697 · Cited by 109
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M., & Pariante, C. M. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.87 · Cited by 110
Open questions in current models of antidepressant action
Tanti, A., & Belzung, C. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00585.x · Cited by 115
Köfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 110
Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000517074 · Cited by 108
New paradigms for treatment‐resistant depression
Zarate, C. A., Duman, R. S., Liu, G., Sartori, S. B., Quiroz, J. A., & Murck, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12223 · Cited by 115
Self-citationMolteni, R., Macchi, F., Zecchillo, C., Dell’Agli, M., Colombo, E., Calabrese, F., Guidotti, G., Racagni, G., & Riva, M. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.008 · Cited by 106
Kim, H. K., Nunes, P. V., de Oliveira, K. C., Young, L. T., & Lafer, B. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.008 · Cited by 112
Wells, A. M., Ridener, E., Bourbonais, C. A., Kim, W., Pantazopoulos, H., Carroll, F. I., Kim, K., Cohen, B. M., & Carlezon, W. A. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0885-17.2017 · Cited by 110
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 112
Self-citationMurrough, J. W., Wan, L.-B., Iacoviello, B. M., Collins, K. A., SOLON, C. A., Glicksberg, B. S., Perez, A. M., Mathew, S. J., Charney, D. S., Iosifescu, D. V., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3255-x · Cited by 113
Self-citationLindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222463 · Cited by 107
Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037916 · Cited by 107
Salvadore, G., van der Veen, J. W. C., Zhang, Y., Marenco, S., Machado‐Vieira, R., Baumann, J., Ibrahim, L. A., Luckenbaugh, D. A., Shen, J., Drevets, W. C., et al. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001593 · Cited by 111
Self-citationZanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
Carhart-Harris, R. L., & Nutt, D. (2010) · Journal of Substance Use · doi:10.3109/14659890903271624 · Cited by 106
Classics in Chemical Neuroscience: Ketamine
Tyler, M. W., Yourish, H. B., Ionescu, D. F., & Haggarty, S. J. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00074 · Cited by 108
Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine
Cui, Y., Hu, S., & Hu, H. (2019) · Trends in Neurosciences · doi:10.1016/j.tins.2018.12.002 · Cited by 111
Merkl, A., Schubert, F., Quante, A., Luborzewski, A., Brakemeier, E., Grimm, S., Heuser, I., & Bajbouj, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.009 · Cited by 110
Schwieler, L., Samuelsson, M., Frye, M. A., Bhat, M., Schuppe‐Koistinen, I., Jungholm, O., Johansson, A. G. M., Landén, M., Sellgren, C. M., & Erhardt, S. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0517-7 · Cited by 107
Witkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Self-citationDeLorenzo, C., DellaGioia, N., Bloch, M. H., Sanacora, G., Nabulsi, N., Abdallah, C. G., Yang, J., Wen, R., Mann, J. J., Krystal, J. H., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.06.024 · Cited by 105
(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0084-y · Cited by 105
Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats
Nemeth, C. L., Paine, T. A., Rittiner, J. E., Béguin, C., Carroll, F. I., Roth, B. L., Cohen, B. M., & Carlezon, W. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1834-7 · Cited by 104
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression
Morris, L. S., Costi, S., Tan, A., Stern, E. R., Charney, D. S., & Murrough, J. W. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0591-5 · Cited by 104
Self-citationMiskowiak, K. W., Vinberg, M., Christensen, E. M., Bukh, J. D., Harmer, C. J., Ehrenreich, H., & Kessing, L. V. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.335 · Cited by 104
Tomaz, V. D. S., Cordeiro, R. C., Costa, A. M. N., de Lucena, D. F., Júnior, H. V. N., de Sousa, F. C. F., Vasconcelos, S. M. M., Vale, M. L., Quevedo, J., & Macêdo, D. S. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.03.025 · Cited by 104
Stroud, J., Freeman, T. P., Leech, R., Hindocha, C., Lawn, W., Nutt, D., Curran, H. V., & Carhart-Harris, R. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4754-y · Cited by 110
Huang, N., Hua, D., Zhan, G., Li, S., Zhu, B., Jiang, R., Yang, L., Bi, J., Xu, H., Hashimoto, K., et al. (2018) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2018.12.001 · Cited by 103
A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics
Savalia, N. K., Shao, L.-X., & Kwan, A. C. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.008 · Cited by 104
A systematic review of off-label uses of memantine for psychiatric disorders
Zdanys, K. F., & Tampi, R. R. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.01.008 · Cited by 105
Serotonin 2C receptor antagonists induce fast-onset antidepressant effects
Opal, M. D., Klenotich, S. C., Morais, M., Bessa, J., Winkle, J., Doukas, D., Kay, L. J., Sousa, N., & Dulawa, S. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.144 · Cited by 103
Gass, N., Schwarz, A. J., Sartorius, A., Schenker, E., Risterucci, C., Spedding, M., Zheng, L., Meyer‐Lindenberg, A., & Weber‐Fahr, W. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.290 · Cited by 107
Lindholm, J., Autio, H., Vesa, L., Antila, H., Lindemann, L., Hoener, M. C., Skolnick, P., Rantamäki, T., & Ċastrén, E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.015 · Cited by 102
Roles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 104
Nugent, A. C., Robinson, S. E., Coppola, R., Furey, M. L., & Zarate, C. A. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.051 · Cited by 103
Self-citationNeuroplasticity and major depression, the role of modern antidepressant drugs
Serafini, G. (2012) · World Journal of Psychiatry · doi:10.5498/wjp.v2.i3.49 · Cited by 105
Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults
McCloud, T. L., Caddy, C., Jochim, J., Rendell, J. M., Diamond, P. R., Shuttleworth, C., Brett, D., Amit, B. H., McShane, R., Hamadi, L., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011611.pub2 · Cited by 102
Cultural Differences and Information Technology Acceptance
Zakour, A. B. (2004) · Cited by 101
Brain region–specific action of ketamine as a rapid antidepressant
Chen, M., Ma, S., Liu, H., Dong, Y., Tang, J., Ni, Z., Tan, Y. J., Duan, C.-C., Li, H., Huang, H., et al. (2024) · Science · doi:10.1126/science.ado7010 · Cited by 105
Evidence‐based treatment strategies for treatment‐resistant bipolar depression: a systematic review
Sienaert, P. A., Lambrichts, L., Dols, A., & Fruyt, J. D. (2012) · Bipolar Disorders · doi:10.1111/bdi.12026 · Cited by 106
A Word to the Wise About Ketamine
Schatzberg, A. F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101434 · Cited by 102
Synaptic Mechanisms Regulating Mood State Transitions in Depression
Parekh, P. K., Johnson, S. B., & Liston, C. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-110920-040422 · Cited by 101
Tornese, P., Sala, N., Bonini, D., Bonifacino, T., La Via, L., Milanese, M., Treccani, G., Seguini, M., Ieraci, A., Mingardi, J., et al. (2019) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100160 · Cited by 101
Fukumoto, K., Iijima, M., & Chaki, S. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3378-0 · Cited by 102
Faster, better, stronger: Towards new antidepressant therapeutic strategies
O’Leary, O. F., Dinan, T. G., & Cryan, J. F. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.046 · Cited by 104
Therapeutic options in treatment-resistant depression
Vieta, E., & Colom, F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.583675 · Cited by 101
Biomarkers of Epileptogenesis: Psychiatric Comorbidities (?)
Kanner, A. M., Mazarati, A. M., & Koepp, M. J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0271-4 · Cited by 104
Cui, W., Ning, Y., Hong, W., Wang, J., Liu, Z., & Li, M. D. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1306-3 · Cited by 102
Athira, K. V., Bandopadhyay, S., Samudrala, P. K., Naidu, V. G. M., Lahkar, M., & Chakravarty, S. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191001142934 · Cited by 110
Jelen, L. A., & Stone, J. M. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2020.1854194 · Cited by 112
Deyama, S., Bang, E., Wohleb, E. S., Li, X., KATO, T., Gerhard, D. M., Dutheil, S., Dwyer, J. M., Taylor, S. R., Picciotto, M. R., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17121368 · Cited by 99
Zheng, W., Cai, D.-B., Xiang, Y.-Q., Zheng, W., Jiang, W., Sim, K., Ungvari, G. S., Huang, X., Huang, X.-X., Ning, Y., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.002 · Cited by 101
Verdonk, F., Petit, A.-C., Abdel-Ahad, P., Vinckier, F., Jouvion, G., de Maricourt, P., De Medeiros, G. F., Danckaert, A., Van Steenwinckel, J., Blatzer, M., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.033 · Cited by 99
A Synaptic Locus for TrkB Signaling Underlying Ketamine Rapid Antidepressant Action
Lin, P.-Y., Ma, Z. Z., Mahgoub, M., Kavalali, E. T., & Monteggia, L. M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109513 · Cited by 99
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Self-citationInvolvement of Sigma-1 Receptors in the Antidepressant-like Effects of Dextromethorphan
Nguyen, L., Robson, M. J., Healy, J. R., Scandinaro, A. L., & Matsumoto, R. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089985 · Cited by 99
Witkin, J. M., Overshiner, C. D., Li, X., Catlow, J. T., Wishart, G. N., Schober, D. A., Heinz, B. A., Nikolayev, A., Tolstikov, V., Anderson, W. H., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.216804 · Cited by 101
Carhart-Harris, R. L., Mayberg, H. S., Malizia, A. L., & Nutt, D. (2008) · Annals of General Psychiatry · doi:10.1186/1744-859x-7-9 · Cited by 113
Comorbidity Factors and Brain Mechanisms Linking Chronic Stress and Systemic Illness
Đurić, V., Clayton, S., Leong, M. L., & Yuan, L. (2016) · Neural Plasticity · doi:10.1155/2016/5460732 · Cited by 110
Metadata
- Authors
- Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K.
- Affiliations
- National Institutes of Health (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-01
- Volume
- 63
- Issue
- 8
- Pages
- 856
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2109334244
- Semantic Scholar
- 3e83c317059846d97106b64a4befc4c24b87e3d1
- Cited by
- 3,766
- References
- 62
- Citations by year
- 2026: 125 · 2025: 186 · 2024: 240 · 2023: 197 · 2022: 222 · 2021: 249 · 2020: 404 · 2019: 229 · 2018: 233 · 2017: 202 · 2016: 237 · 2015: 223 · 2014: 190 · 2013: 206 · 2012: 159
- FWCI
- 48.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, NMDA receptor antagonists, treatment-resistant depression, major depressive disorder, rapid antidepressant effects, intravenous infusion, glutamatergic system, antidepressant onset of action, remission
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome, Cross-Over Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
